🔗 Share this article

While the US proceeds with historic revisions to its vaccination schedules, one figure has surfaced unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccinations during the pandemic and has focused upon potential fatalities after COVID-19 immunization in her brief position at the Food and Drug Administration.

Planned Changes to Childhood Immunization Schedule

Health officials planned to reveal radical changes to the childhood vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of alignment with much of the world with no evidence for improved outcomes. The announcement has been postponed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was just designated interim head of the FDA’s CDER, the fifth appointee to head the division this year.

A New Direction at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine centers as Høeg and Prasad consolidate power at the FDA – and it signals a renewed priority upon rolling back previously authorized immunizations at the FDA.

Høeg has frequently advocated for ending certain childhood vaccine recommendations in the US so as to align more like Denmark's approach, a country with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on immunizations – typically the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Background

Høeg has little discernible experience in pharmaceutical research, regulation or administrative roles, which has been typical for past heads of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for overseeing the CDER, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Former commissioners of the center would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who led the center have had.”

This division has an enormous portfolio at the agency, Woodcock emphasized.

“Many people just pays attention on the innovative therapies, but the generic drug division clears numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and every single one have to be supervised,” Dr. Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant administrative element to the job, which supervises in excess of 5,000 staff members. “It is a huge administrative position, if you perform it correctly,” she concluded.

Response and Disputed Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this assignment indicates more teamwork among agency officials on vaccines, a press secretary said that the “concerns rely on inaccurate assumptions”.

“Her resume is consistent with the duties of her job,” the official said, pointing to the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious expedited therapy clearance system that apparently worried her preceding directors. “How are these therapies being chosen for this fast-track system? Who takes the calls?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards less stringent regulations of most medications, except for shots.”

Public Past Work on Immunizations

With immunizations, Høeg has a more documented, if troubling, past, Howard observe. She published a analysis using non-validated crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the incoming government encompassed changing regulations for recently developed shots and discontinuing “optional” immunizations, she remarked after the election on a online show. At the agency, Høeg has allegedly suggested excluding young men from getting COVID-19 vaccinations.

“She is an all-around ideologue who begins with her beliefs and works backwards to retrofit the data in a extremely deceptive, dishonest manner,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of other skeptics, {like|